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Boosting innate immunity in cancer
 
Mature DCs and the NKT cell ligand 
 
 
 
-galactosyl ceramide (
 
 
 
-GalCer) are a 
promising combination for boosting immunity in humans, according to a study on 
page 1503. Chang and colleagues used 
 
 
 
-GalCer–pulsed DCs to immunize
cancer patients and showed that the treatment resulted in long-term expansion 
of both NKT cells and virus-specific CD8
 
 
 
 T cells.
 
 
 
-GalCer, a glycolipid derived from marine sponges, was identified based on 
its antitumor properties. This foreign glycolipid was later found to be presented 
to NKT cells by DCs. NKT cells activated by this glycolipid can promote tumor 
regression in mice. Attempts to extend this work to humans, however, have met 
with limited success. 
 
 
 
-GalCer treatment alone decreased NKT cell numbers in 
patients with solid tumors, and vaccination with 
 
 
 
-GalCer–pulsed immature DCs 
induced only modest and transient NKT cell expansion.
Maturation of the DCs—treatment with cytokines that enhance the 
expression of MHC and costimulatory molecules—was the key to the approach 
used by Chang and colleagues. They immunized five advanced cancer patients, 
none of whom had detectable NKT cells in their blood before treatment. But with 
 
 
 
-GalCer–pulsed mature DCs, all patients had a rapid and sustained increase in 
NKT cell numbers.
Surprisingly, CD8
 
 
 
 T cells specific for cytomegalovirus were also expanded by 
 -GalCer–pulsed DCs activate NKT cells and 
antiviral T cells in advanced cancer patients.
 
the treatment, suggesting that this approach might also be useful to boost immunity to chronic viral 
infections like HIV or hepatitis C virus, or to enhance the efficacy of T cell–based vaccines.
 
Turning fat into muscle
 
Stem cells from fat tissue have the po-
tential to become muscle, bone, or fat,
according to a study by Rodriguez
and colleagues on page 1397. These
stem cells rescued the production of
the muscle protein dystrophin in a
mouse model of Duchenne muscu-
lar dystrophy (DMD), a fatal muscle
wasting disease of children. The authors
think that these cells may eventually
be promising for treatment of children
with this deadly, and thus far untreat-
able, disease.
DMD is caused by a lack of the
cytoskeletal protein dystrophin, which
provides muscle cells with structural
stability. Several treatment strategies
for DMD are under investigation, in-
cluding gene therapy to replace the de-
fective dystrophin gene, and stem cell
transplantation to generate new dystro-
phin-producing muscle cells.
Previous work by this group and
others revealed the presence of stem cells
in human fat tissue, but their longevity in
vitro and capacity to differentiate in vivo
had not been explored. Rodriguez et al.
now show that fat tissue from young
donors yielded self-renewing stem cells
that could differentiate into muscle,
bone, or fat cells in culture, even after
100 or more cell divisions. Similar stem
cells have been found previously in bone
marrow, but fat, the authors point out,
provides a more plentiful and easily
accessible source of these cells.
Injection of the stem cells into the
muscles of dystrophin-deficient mice
restored dystrophin production and de-
creased  muscle cell necrosis, without
eliciting an immune response against the
human dystrophin protein—a protein
that is normally highly immunogenic in
mice. Why the immune system does
not respond to this foreign protein is
not known.
Another unknown is how these
stem cells become dystrophin-producing
muscle cells. One possibility—illustrated
in recent reports of stem cell therapy in
mice—is that the stem cells fuse with
local tissue cells rather than differentiating
de novo into new cells.
Stem cells from human fat differentiate into muscle cells and produce dystrophin (green) 
when injected into mice.
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